Kancera Logo

Kancera

Pharmaceutical company seeking a reverse takeover to leverage its public listing.

KAN | ST

Overview

Corporate Details

ISIN(s):
SE0015658570 (+1 more)
LEI:
5493002P3RCOFW6HI207
Country:
Sweden
Address:
Nanna Svartz väg 4, 171 65 SOLNA

Description

Novakand Pharma AB, formerly Kancera AB, is a pharmaceutical company that was focused on the development of small molecule therapeutics. Its primary research areas included cancer and inflammatory diseases. The company's pipeline featured drug candidates targeting the fractalkine system for cardiovascular and inflammatory conditions, as well as ROR inhibitors for oncology applications such as leukemia and solid tumors. Following a strategic review prompted by challenging capital market conditions, the company has initiated a process to seek a reverse takeover, aiming to leverage its public listing and cash assets for a merger with another entity.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kancera filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kancera

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kancera via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

OncoTherapy Science, Inc. Logo
Biopharmaceutical company researching and developing novel anti-cancer therapies.
Japan
4564
Optipharm.CO.,LTD Logo
Develops animal health solutions, biotherapeutics, and xenotransplantation technology.
South Korea
153710
ORAGENICS INC Logo
Biotechnology company developing intranasal therapeutics for neurological disorders.
United States of America
OGEN
Develops organoid-based technologies for drug development and regenerative medicine.
South Korea
476040
Orum Therapeutics, Inc. Logo
Clinical-stage biotech developing degrader-antibody conjugates to treat cancer.
South Korea
475830
OSR Holdings, Inc. Logo
A healthcare holding company acquiring and developing innovative therapies and solutions.
United States of America
OSRH
OS Therapies Inc Logo
Clinical-stage immunotherapy company developing treatments for HER2-positive cancers.
United States of America
OSTX
OXFORD BIODYNAMICS PLC Logo
Develops and commercializes precision medicine tests for oncology using 3D genomics.
United Kingdom
OBD
Oxurion NV Logo
Acquires majority stakes in European pharmaceutical subcontractors.
Belgium
OXUR
Pasithea Therapeutics Corp. Logo
Develops treatments for central nervous system disorders, RASopathies, and solid tumors.
United States of America
KTTA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.